Decoding SRRK’s 8-K Tea Leaves: HOLD or FOLD After the Auditor Shuffle?
Scholar Rock Holding Corporation (SRRK) Ditches Old Auditor, Snags Deloitte: What’s the Deal? Welcome back to the ongoing saga of Scholar Rock Holding Corporation (SRRK),...
Biotech Stocks
-
-
RGNX Shareholders Unleash Rocket Fuel: Is This Liftoff to the Moon? (New 8-K)
REGENXBIO Inc. Gets Shareholder Thumbs Up: Full Speed Ahead on Gene Therapy Dreams? (Updated June 04, 2025) Welcome back to the REGENXBIO Inc. (RGNX) saga,...
-
No Cardiotoxicity, High CBR: Does MBRX’s Latest Filing Signal a Breakout?
Annamycin Shines in Sarcoma Study: Moleculin Biotech (MBRX) Delivers Promising Results (But Hold Your Horses, Folks!) Welcome back to the ongoing saga of Moleculin Biotech...
-
LXRX Reverse Split Incoming? Decoding the Latest SEC Filing Tea Leaves.
Lexicon Pharmaceuticals Stock Split Incoming? Plus, a Juicy Equity Shake-Up! (LXRX 8-K Deep Dive) Welcome back to the Lexicon Pharmaceuticals chronicles, dear readers! Your resident...
-
FDA Greenlights KURA’s NDA: Is This the Rocket Fuel Your Portfolio Needs?
KURA Oncology’s Ziftomenib NDA Accepted by FDA: Is This the Leukemia Breakthrough We’ve Been Waiting For? (June 2025 Update) Welcome back to the ongoing saga...
-
Reading Between the Lines: What INAB’s Reverse Split REALLY Means for Your Portfolio.
IN8bio Stock Split: One Giant Leap for Share Price, One Small Step for Investors? 🤔 Welcome back to the ongoing saga of IN8bio, a company...
-
ENVB’s Future on the Line: What the Low Voter Turnout *Really* Means.
Enveric Biosciences Stockholders Approve Reverse Split (Barely): What’s the Deal? Welcome back to the ongoing saga of Enveric Biosciences (ENVB)! Consider this your definitive guide...
-
DNLI & Baker Bros: Power Move or Exit Strategy? Decoding the Latest SEC Filing.
Baker Brothers Gets Cozy with Denali Therapeutics: A Board Seat and Easier Stock Sales – What’s the Deal? Welcome back to the ongoing saga of...
-
CRVS Stock: Decoding the Latest SEC Filings – Is a Moon Mission Imminent?
Corvus Pharma (CRVS) Soquelitinib Trial: Itch Less, Scratch More (Profits)? 🤑 Welcome back to the ongoing saga of Corvus Pharmaceuticals, where we decode the latest...
-
CGTX’s EAP Gambit: Is This Dementia Drug the Next Biotech Moonshot?
Cognition Therapeutics Gets a Philanthropic Boost: Zervimesine Expanded Access Program for DLB Launched! Welcome back to the ongoing saga of Cognition Therapeutics (CGTX), where we...
-
BJDX’s Desperate Gamble: Downsizing & Praying for a Miracle? SEC Filing Breakdown.
Bluejay Diagnostics: Downsizing, Cash Crunch, and a $30 Million Question Mark – The June 2025 Update Welcome back to the ongoing saga of Bluejay Diagnostics...
-
ALLR’s Stenoparib Breakthrough: Decoding the SEC Files & the Path to Big Gains.
Allarity Therapeutics Pops the Cork on Phase 2 Trial: Is This Stenoparib’s Time to Shine? Welcome back to the ongoing saga of Allarity Therapeutics! Consider...